Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study.
Gu J, Zhang H, Xue Q, Wang L, Cheng Z, Zhang Y, Li Q, Yuan L, Li Y, Dong J, Huo Y, Tang X, Hu L, Wang X, Hua F, Shen L, Cheng J, Zhou H, Xu Y, Yang T, Wang C, Xu J, Shen J, Zhang Y, Zhang X, Hong D, Guan X, Xiao X, Wang G, Liu Y, Fu L, Chen J, Cheng X, Ding Y, Liu L, Yao Q, Zhang X, Li L, Zhang P, Deng C, Jiang C, You L, Wang K, Zhang S, Xiao J, Liu W, Du X, Shang X, Pan T, Lei C, Guo S, Zhang Z. Gu J, et al. Among authors: cheng z, cheng j, cheng x. J Orthop Translat. 2022 Oct 29;38:117-125. doi: 10.1016/j.jot.2022.06.007. eCollection 2023 Jan. J Orthop Translat. 2022. PMID: 36381249 Free PMC article.
Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Weng J, Zeng L, Zhang Y, Qu S, Wang X, Li P, Fu L, Ma B, Ye S, Sun J, Lu W, Liu Z, Chen D, Cheng Z, Liu H, Zhang T, Zou J. Weng J, et al. Among authors: cheng z. Diabetes Obes Metab. 2021 Aug;23(8):1754-1764. doi: 10.1111/dom.14389. Epub 2021 Apr 14. Diabetes Obes Metab. 2021. PMID: 33769656 Clinical Trial.
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
Yang W, Dong X, Li Q, Cheng Z, Yuan G, Liu M, Xiao J, Gu S, Niemoeller E, Chen L, Ping L, Souhami E; LixiLan-O-AP trial investigators. Yang W, et al. Among authors: cheng z. Diabetes Obes Metab. 2022 Aug;24(8):1522-1533. doi: 10.1111/dom.14722. Epub 2022 May 12. Diabetes Obes Metab. 2022. PMID: 35441412 Clinical Trial.
Jintiange combined with alfacalcidol improves muscle strength and balance in primary osteoporosis: A randomized, double-blind, double-dummy, positive-controlled, multicenter clinical trial.
Liang H, Wang O, Cheng Z, Xia P, Wang L, Shen J, Kong X, Zeng Y, Chao A, Yan L, Lin H, Sun H, Cheng Q, Zhu M, Hu Z, Zhang Z, Tang H, Xia W. Liang H, et al. Among authors: cheng z, cheng q. J Orthop Translat. 2022 Aug 24;35:53-61. doi: 10.1016/j.jot.2022.05.002. eCollection 2022 Jul. J Orthop Translat. 2022. PMID: 36090002 Free PMC article.
GABA Analogue HSK16149 in Chinese Patients With Diabetic Peripheral Neuropathic Pain: A Phase 3 Randomized Clinical Trial.
Guo X, Zhang T, Yuan G, Zeng W, Hu Q, Ma J, Li Y, Li H, Zhang Y, Liu J, Bian F, Zhang W, Zhang F, Pang S, Li Y, Wu X, Tang X, Zhang K, Pan T, Hu H, Cheng Z, Wang Y, Gao J, Sun J. Guo X, et al. Among authors: cheng z. JAMA Netw Open. 2024 Aug 1;7(8):e2425614. doi: 10.1001/jamanetworkopen.2024.25614. JAMA Netw Open. 2024. PMID: 39158916 Free PMC article. Clinical Trial.
A biweekly DPP-4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
He Q, Cheng Z, Li Y, Xing X, Li L, Li X, Zhang J, Xu L, Song W, Li F, Zhang Z, Guo L. He Q, et al. Among authors: cheng z. Diabetes Obes Metab. 2025 Feb;27(2):965-975. doi: 10.1111/dom.16096. Epub 2024 Dec 4. Diabetes Obes Metab. 2025. PMID: 39632416 Clinical Trial.
Epidemiological characteristics of lower extremity arterial disease in Chinese diabetes patients at high risk: a prospective, multicenter, cross-sectional study.
Zhang X, Ran X, Xu Z, Cheng Z, Shen F, Yu Y, Gao L, Chai S, Wang C, Liu J, Liu J, Sun Z, Zhao J, Ji L; China DIA-LEAD Study Investigators. Zhang X, et al. Among authors: cheng z. J Diabetes Complications. 2018 Feb;32(2):150-156. doi: 10.1016/j.jdiacomp.2017.10.003. Epub 2017 Oct 13. J Diabetes Complications. 2018. PMID: 29191431
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Gao L, Cheng Z, Su B, Su X, Song W, Guo Y, Liao L, Chen X, Li J, Tan X, Xu F, Pang S, Wang K, Ye J, Wang Y, Chen L, Sun J, Ji L. Gao L, et al. Among authors: cheng z. Diabetes Obes Metab. 2023 Mar;25(3):785-795. doi: 10.1111/dom.14926. Epub 2022 Dec 12. Diabetes Obes Metab. 2023. PMID: 36433709 Clinical Trial.
10,230 results
You have reached the last available page of results. Please see the User Guide for more information.